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Abstract
Background New strategies have been developed to
expand indications for liver surgery. The objective was to
evaluate the current practice worldwide regarding critical
liver mass and manipulation of the liver volume.
Methods A survey was sent to 133 liver centers world-
wide, which focused on (a) critical liver volume, (b)
preoperative manipulation of the liver mass, and (c) use of
liver biopsy and metabolic tests.
Results The overall response rate to the survey was 75%.
Half of the centers performed more than 100 resections per
year; 86% had an associated liver transplant program. The
minimal remnant liver volume for resection was 25% (15–
40%) in cases of normal liver parenchyma and 50% (25–
90%) in the presence of underlying cirrhosis. The minimal
remnant liver volume for living donors was 40% (30–
50%), whereas the accepted graft body weight ratio was 0.8
(0.6–1.2). Portal vein occlusion to manipulate the liver
volume before resection was performed in 89% of the
centers.
Conclusions Limits of liver volume and the current
practice of liver manipulation before resection were com-
parable among different centers and continents. The
minimal remnant liver volume in normal liver was 25%,
and more than 80% of the centers performed portal vein
occlusion.
Abbreviations
ICG Indocyanine green
PVE Portal vein embolization
PVL Portal vein ligation
SFSS Small-for-size syndrome
GBWR Graft body weight ratio
TACE Transarterialchemoembolization
MRLV Minimal remnant liver volume
LDLT Living donor livertransplantation
DDLT Diseased donor liver transplantation
Introduction
Resection of hepatic tumors is being performed with
increasing frequency worldwide. Novel developments for
the treatment of liver tumors during the past two decades
have been based on improvements in several areas, including
perioperative management [1–3], novel imaging modalities
(particularly positron emission tomography [4, 5]), as well as
better understanding on the mechanisms of liver regenera-
tion [6–8], resulting in the possibility to manipulate the liver
mass before surgery [9]. Moreover, risk factors for postop-
erative liver failure, such as liver steatosis or preoperative
chemotherapy, have been better defined [9, 10].
Regeneration of liver volume, based on the replication
and increase of size of different types of hepatic cells, can
be initiated by partial hepatectomy [6–8] or by selective
occlusion of the portal branches [9, 11]. Based on this
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knowledge, safer strategies, such as unilateral portal vein
embolization or ligation, have been developed to increase
the volume and related function of the potential remnant
liver. In this context, two-stage hepatectomy for initially
unresectable tumors may extend the indications for liver
surgery [12–14].
Regarding liver transplantation, partial liver grafts
(split-liver transplant and living donor liver transplanta-
tion) [9] are now established techniques. The use of so-
called marginal (or extended criteria) organs [15] repre-
sents another strategy to expand the pool of organs. This
survey was designed to gain insight into current practices
in liver surgery among liver surgery specialists worldwide
regarding preoperative assessment of the liver function,
manipulation of liver volume, as well as critical size of
liver volume in liver resection, and orthotopic liver trans-
plantation (OLT).
Methods
Directors or codirectors of 133 hepato-pancreato-biliary
(HPB) and liver transplant centers worldwide (North
America, South America, Asia, Europe, Australia/New
Zealand, and Africa) were invited to participate in the
survey. Many HPB surgeons were personally contacted to
complete the questionnaire during the meetings of the
European Surgical Association (ESA) and the International
Hepato-Pancreato-Biliary Association (IHPBA). The sur-
vey was additionally forwarded to leading HPB surgeons at
other centers worldwide known through personal networks.
Reminder emails were sent as many as three times every
4 weeks. The survey was closed on September 2007.
This HPB surgery and liver transplantation question-
naire consisted of three main topics to assess current
practices in liver surgery and OLT: (a) critical liver volume
in liver resection and living donor liver transplantation
(LDLT), (b) manipulation of liver mass before surgery, and
(c) use of liver biopsy and metabolic tests to assess liver
function before surgery. Although the names of the sur-
geons and the centers were mentioned in the questionnaire,
data were reported anonymously (Fig. 1). Results are
expressed in percentages, medians, and ranges.
Results
Participating centers
One hundred directors or codirectors from four continents
replied to the questionnaire, yielding a high response rate
of 75%. The geographic distribution is shown in Fig. 2.
Sixty-three European centers were approached, 36 from
North America, 20 from Asia, 7 from South America, 5
from Australia-New Zealand, and 2 from Africa. Almost
half of the responders were from Europe (n = 48), a rel-
evant number of replies were from North America
(n = 27) and Asia (n = 17), whereas a minority were from
Australia/New Zealand (n = 4) and South America
(n = 4). No replies were received from Africa. The highest
response rate was in Asia (85%; Fig. 2).
Half of the centers (51%) performed more than 100 liver
resections per year, whereas one-third (32%) performed
between 50 and 100 liver resections annually. The
remaining 17% (n = 17) of the centers performed up to 50
liver resections per year (Fig. 2).
Eighty-six percent of the 100 HPB centers also per-
formed OLT, and most of them (72 centers, 83%) also
performed LDLT. The majority of centers performed more
than 50 OLT per year (61.5%; Fig. 3).
Critical remnant liver mass after liver resection
or LDLT
In normal livers, the median of the minimal remnant vol-
ume accepted after resections was 25% of the total liver
volume (15–40%), whereas in cirrhotic patients the mini-
mal remnant liver volume was 50% (25–90%; Table 1).
Regarding LDLT, the minimal remnant donor volume
was 40% (range 30–50%) of the total liver volume. The
minimal Body Graft Weight Ratio (BGWR) for recipients
of LDLT was 0.8 (range 0.6–1.2). Values differentiated per
continent are disclosed in Table 1.
Portal vein occlusion
Preoperative manipulation of liver mass, usually by uni-
lobar portal vein occlusion though portal vein embolization
or portal vein ligation was performed selectively in 89%
(n = 89) of the centers, but with an average frequency of
less than 1 in 10 patients (range 1–70%). The main reason
was a predicted small remnant liver (72 centers; 80.8%).
Other indications were major resections in cirrhotic or
steatotic livers (11.2%) or cholangiocarcinoma patients
(6.7%) regardless of the volume. Sixty-eight centers
exclusively performed portal vein embolization. Seven
centers sometimes combined portal vein embolization with
transarterial chemoembolization, and nine centers also
performed portal vein ligation (Table 2).
Preoperative liver and tumor biopsy
Seventy-three of 100 centers (73%) used liver biopsy of the
nontumoral parenchyma before resection, but most of them
applied this strategy selectively (93.1%; n = 68). The most
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common reason for liver biopsy was the assessment of
underlying liver disease in patients suffering from hepa-
tocellular carcinoma; this was performed routinely in five
centers (6.8%) and selectively in 80% of the centers.
Preoperative metabolic liver tests
Metabolic tests before major liver resections were per-
formed in 38 centers (38%). Nearly half of these centers
(18 centers; 47.4%) performed them routinely, whereas the
other half (20 centers; 52.6%) used them selectively. When
selectively used, the assessment of liver function in dis-
eased organs (e.g., steatosis or cirrhosis) was the main
indication (n = 20; 100%). The most commonly used
metabolic liver tests were the indocyanine green (ICG) test
(n = 29; 76.3%) and the amino-breath test (n = 4; 10.5%).
Regarding continental distribution of the use of preopera-
tive metabolic tests, Asia ranked first (76% of the centers)
followed by Europe (43%), Australia (20%), and North
America (11%). Metabolic liver tests were not used in the
four South American centers surveyed (Table 3a–c).
Discussion
This survey provides comprehensive insight into the
modern practice of liver surgery in specialized centers. One
hundred centers, mainly high-volume HPB and liver
Name: _______________ Country/City: ________________________________ 
1. How many hepatectomies does your institution perform each year? 
10 10-25     25-50     50-100 more than 100 
2. What is the minimal remnant liver volume that you would accept for liver resection? 
    Normal liver:    ___% of total liver volume
    Cirrhotic liver:  ___%of total liver volume 
3. Do you use portal vein embolization (PVE) or other strategies to manipulate the liver mass 
    before liver resection? 
  No 
  Yes, PVE 
  Yes, other (Please specify: ___________________ ) 
4. In which situations do you use PVE? 
______________________________________________________________________ 
5. If you use PVE, in how many percent of your liver resections do you use PVE (estimation). 
    ___% of liver resections 
6. Do you use liver biopsies before liver resection? 
  Never 
  Routinely 
  Selectively (Please specify indications: __________________________________)
7. Do use metabolic tests (ICG, etc.) to assess liver function before major hepatecomy? 
  No 
  Yes (Please specify which test: ____________________ ) 
8. If you use metabolic tests, what is your policy to use them? 
  Never 
  Routinely in each patients before major hepatectomy 
  Only in cirrhotic and/or steatotic livers 
     Other indications (Please specify: ___________________ ) 
9. How many liver transplantations does your institution perform each year? 
10 10-25     25-50     50-100 more than 100 
10. What is the minimal remnant donor liver volume that you would accept in living donor liver 
      transplantation? 
      ___% of total liver volume 
11. What is the minimal viable graft volume that you would accept for recipients in living donor liver 
transplantation?
       ___% of graft/ body volume
Fig. 1 International
questionnaire on manipulating
the liver mass
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transplantation centers, throughout the world were evalu-
ated. The critical size of remnant liver after resection was
25% in the presence of normal liver parenchyma and 50%
in cirrhotic patients. Eighty-nine percent of the liver cen-
ters used preoperative strategies to manipulate the liver
mass, most frequently portal vein occlusion.
There is a worldwide trend to concentrate complex liver
surgery in high-volume centers, because it is widely
accepted that morbidity and mortality for major surgery
correlate with the case-load of the hospital and the expe-
rience of the team [16, 17]. In complex HPB surgery as for
other complex procedures, outcome improvements are not
solely based on the experience of a surgeon but also on the
Table 1 Critical liver mass for liver resection and partial liver transplantation
Normal liver (%) Cirrhotic liver (%) Donor volume in LRLT (%) Graft-body-weight-ratio
Europe 28 (15–40) 50 (30–80) 35 (30–50) 0.8 (0.6–1.2)
North America 25 (15–30) 50 (25–90) 35 (30–45) 0.8 (0.8–1)
Asia 30 (20–40) 50 (30–80) 35 (30–45) 0.8 (0.6–0.8)
Australia 28 (25–30) 50 (40–50) 35 –
South America 28 (25–40) 45 (40–80) 38 (35–40) 0.8 (0.8–1.2)
Overall 25 (15–40) 50 (25–90) 40 (30–50) 0.8 (0.6–1.2)
Data are expressed as medians and ranges unless otherwise indicated
Table 2 Preoperative portal vein occlusion (PVO)
PVO Frequency of PVO
Europe 47 (97) 10% (2–20%)
North America 23 (85) 5% (2–20%)
Asia 14 (82) 8% (1–70%)
Australia 2 (40) 10% (10–10%)
South America 3 (75) 10% (5–16%)
Overall 89 (89) 8% (1–70%)
Data expressed as numbers with percentages in parentheses and
median with ranges in parentheses
Table 3 (a–c) Use of metabolic tests to assess liver function before
liver surgery
n %
(a) Use of metabolic tests
Europe 21 43
North America 3 11
Asia 13 76
Australia 1 20
South America 0 0
Overall 38 38
(b) Type of metabolic tests
ICG 29 76.4
Breath tests 4 10.5
GSA scintigraphy 2 5
Other (no details) 3 7.9
(c) Indications of metabolic tests
Routinely 18 47.4
Selectively 20 52.6
ICG indocyanine green
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availability of facilities, such as anesthesia, intensive care
unit, and nursing [18]. The critical number for liver
resections per center is not completely standardized,
whereas for pancreatic surgery (Whipple procedure), a
high-volume center should perform more than 50 pancre-
atic resections per year [19]. In the current survey, the vast
majority of participating centers ([80%) performed a high
volume of more than 50 liver resections and more than 50
liver transplantations per year. Therefore, we would spec-
ulate that the results of this survey are highly representative
regarding the current ‘‘state of the art’’ of liver surgery
throughout the world.
Impaired liver function of the remaining liver is of
major concern for the HPB surgeon, particularly in patients
with some degree of underlying liver diseases. Today the
standard to estimate the remnant volume is based on vol-
umetric techniques using MR- or CT-data sets [20, 21].
Below a certain volume, a remnant liver cannot sustain
metabolic, synthetic, and detoxifying functions. Symptoms,
such as jaundice, coagulopathy, encephalopathy, ascites, as
well as renal and pulmonary failure, have been termed the
‘‘small-for-size syndrome’’ [22, 23]. Although a number of
risk factors for postoperative liver failure are known [9],
critical remnant liver volumes in humans have not been
evaluated on a scientific basis. Belghiti et al. reported an
incidence of 9% of small remnant liver (defined as \30%
of total liver volume) after major hepatectomies (C3 seg-
ments) [24]. Liver cirrhosis is the best-studied underlying
liver disease in patients undergoing resection, which is
associated with lower tolerance of tissue loss, given its
impaired function and decreased ability to regenerate [25].
Additional portal hypertension, associated with a
compromised portal flow, correlates with a high risk of
postoperative liver failure and death even after minor liver
resection [26]. In the present study, the median of the
minimal remnant volume after resection in normal liver
was 25% (range 15–40%), whereas in cirrhotic patients the
replies were much more inhomogeneous, ranging from 25
to 90% (median, 50%) without differences among conti-
nents and interestingly also without differences between
centers with or without a transplantation program. These
data are consistent with a recent review published by
Clavien et al. [9].
Graft function in liver transplantation depends on sev-
eral characteristics of the donor as well as of the recipient
[27, 28]. Particularly in LDLT, volume of the graft liver
and volume of the remnant liver of the donor are critical for
success. Regarding the recipient, a minimal graft body
weight ratio of 0.8 has been widely reported [9, 29, 30],
which is consistent with the practice in most of the centers
(Fig. 2).
Regarding living donors, the current evaluation of the
median remnant liver volume was 40% (range 30–50%),
which is in accordance with published data [9, 31, 32].
According to Tan et al. a safe donation is not possible with
a volume of \30% of the remnant liver [31]. Because the
volume of segments V–VIII ranged between 50–80% of
the liver volume in cadaveric studies, it is expected that at
least 25% of potential donors will have a left liver vol-
ume \30% [32]. In this situation, if a left liver graft
(segments I–IV) was not large enough and no cadaveric
donor was available, the utilization of a right posterior
graft (segments VI–VII) or a dual graft have been reported
[30].
Several strategies have been developed to minimize the
subsequent risk of liver failure after major liver resection.
In 1990, Makuuchi et al. first described that selective
occlusion of the right branch of the portal vein may
improve outcome after major hepatectomy [33]. Selective
interruption of the portal flow to a portion of the liver
causes atrophy of the ipsilateral hemiliver and hypertrophy
of the contralateral side and can be achieved by portal vein
embolization or ligation. Both approaches of portal vein
occlusion and ligation were usually performed to close the
right portal vein in preparation for a right (removal of
segments V–VIII) or an extended right hepatectomy (and
removal of segment IV) [33–37]. The additional occlusion
of the left medial branch (segment IV) may increase the
regeneration of the left liver segments, particularly before
extended right hepatectomy [37].
Selective portal vein occlusion has been recently inte-
grated into several strategies for two-stage hepatectomy for
advanced liver tumors [9, 14, 38, 39] to extend the limits of
respectability, and therefore, provide a curative treatment
option for many patients, otherwise considered unsuitable
for a curative option. The maximal growth of liver volume
is reached 2–4 weeks after portal vein occlusion [40] and
normally affords an extended liver resection at this time.
According to the present evaluation, the manipulation of
the liver mass by selective portal vein occlusion is well
implemented throughout the world in specialized centers
(89% of liver centers); however, the mean frequency of
application remains relatively low (8%, with a large range
of 1–70%; Table 2). Small predicted remnant liver was the
main indication to use selective portal vein occlusion.
The presence of underlying liver diseases increases the
risk for postoperative liver failure after hepatectomy [9],
although which degree of disease negatively impact on
outcome remains largely unknown. Liver biopsy is still the
standard modality for identifying liver pathologies, such as
steatosis, fibrosis, cirrhosis, or hepatitis. Less invasive
techniques, such as MR elastography [41] or ultrasound
stiffness measurements [42], may provide valuable infor-
mation in the future.
Metabolic tests allow analysis of different metabolic
pathways by measuring the pharmaco-kinetics of an
World J Surg (2009) 33:797–803 801
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exogenous substance eliminated by the liver to assess the
preoperative liver function. Indiocyanine green test is the
most commonly applied metabolic test; however, the rate
of retention of indocyanine is influenced by several factors,
especially the liver flow [36, 43]. The retention rate at 15
minutes and plasma disappearance rate are the standard
values to predict liver function. Despite its theoretical
advantages, the ICG test is not yet accepted worldwide.
Although in western countries, the ICG test is not thought
to be reliable, it is widely incorporated in the decision
making in eastern countries. Preoperative quantitative
liver-function tests were used in more than one-third (38%)
of the centers participating in the present survey. In Asia,
the rate of preoperative metabolic tests was significantly
higher than in the other continents (76%). Particularly
Americans have a completely different practice, with only
11% of the centers performing metabolic tests before
surgery.
A limitation of the survey is a potential selection bias of
included centers. It is in the nature of a survey that only a
selection of population is approached and only part of the
surveyed surgeons may reply. Leading surgeons in the field
of liver surgery in all continents were contacted at two of
the most important international congresses. The present
evaluation included a high number of specialized centers
with a high rate of replies (75%). Therefore, we speculate
that this evaluation is well representative of the opinion and
current practice in major HPB centers, although some
continents has more representation in the survey. We are
not aware of the availability of similar data.
Conclusions
This survey provides an overview of current practices in
liver surgery and transplantation worldwide. A transplan-
tation program is in place in almost all high-volume HPB
centers. Selective portal vein occlusion is well imple-
mented in most specialized centers throughout the world.
Preoperative liver biopsy and functional liver tests are
applied selectively by most surgeons, with remarkable
differences between eastern and western countries.
Although the mean critical liver mass for resections and
LDLT is similar across the continents, the ranges are high
and may require further evaluation and consensus on safety
in liver surgery.
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